1	4	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Discussion	_	_	NN	_	_	_	_	_


1	iSGLT2s	_	_	NNS	_	_	_	_	_
2	are	_	_	VBP	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	new	_	_	JJ	_	_	_	_	_
5	class	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	oral	_	_	JJ	_	_	_	_	_
8	hypoglycaemic	_	_	JJ	_	_	_	_	_
9	drugs	_	_	NNS	_	_	_	_	_
10	that	_	_	WDT	_	_	_	_	_
11	block	_	_	VBP	_	_	_	_	_
12	glucose	_	_	NN	_	_	_	_	_
13	reabsorption	_	_	NN	_	_	_	_	_
14	at	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	renal	_	_	JJ	_	_	_	_	_
17	level	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	thus	_	_	RB	_	_	_	_	_
20	promoting	_	_	VBG	_	_	_	_	_
21	urine	_	_	NN	_	_	_	_	_
22	glucose	_	_	NN	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	sodium	_	_	NN	_	_	_	_	_
25	excretion	_	_	NN	_	_	_	_	_
26	and	_	_	CC	_	_	_	_	_
27	reducing	_	_	VBG	_	_	_	_	_
28	plasma	_	_	NN	_	_	_	_	_
29	glucose	_	_	NN	_	_	_	_	_
30	levels	_	_	NNS	_	_	_	_	_
31	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	present	_	_	JJ	_	_	_	_	_
4	study	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	we	_	_	PRP	_	_	_	_	_
7	have	_	_	VBP	_	_	_	_	_
8	focused	_	_	VBN	_	_	_	_	_
9	on	_	_	IN	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	effects	_	_	NNS	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	empagliflozin	_	_	NN	_	_	_	_	_
14	on	_	_	IN	_	_	_	_	_
15	oxidative	_	_	JJ	_	_	_	_	_
16	stress	_	_	NN	_	_	_	_	_
17	in	_	_	IN	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	leukocytes	_	_	NNS	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	T2D	_	_	NN	_	_	_	_	_
22	subjects	_	_	NNS	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	and	_	_	CC	_	_	_	_	_
25	on	_	_	IN	_	_	_	_	_
26	inflammatory	_	_	JJ	_	_	_	_	_
27	parameters	_	_	NNS	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	addition	_	_	NN	_	_	_	_	_
3	to	_	_	TO	_	_	_	_	_
4	a	_	_	DT	_	_	_	_	_
5	reduction	_	_	NN	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	body	_	_	NN	_	_	_	_	_
8	weight	_	_	NN	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	an	_	_	DT	_	_	_	_	_
11	improved	_	_	VBN	_	_	_	_	_
12	metabolic	_	_	JJ	_	_	_	_	_
13	profile	_	_	NN	_	_	_	_	_
14	—	_	_	:	_	_	_	_	_
15	characterized	_	_	VBN	_	_	_	_	_
16	by	_	_	IN	_	_	_	_	_
17	reduced	_	_	VBN	_	_	_	_	_
18	plasma	_	_	NN	_	_	_	_	_
19	glucose	_	_	NN	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	HbA1c	_	_	NN	_	_	_	_	_
22	levels	_	_	NNS	_	_	_	_	_
23	—	_	_	:	_	_	_	_	_
24	we	_	_	PRP	_	_	_	_	_
25	observed	_	_	VBD	_	_	_	_	_
26	a	_	_	DT	_	_	_	_	_
27	reduction	_	_	NN	_	_	_	_	_
28	in	_	_	IN	_	_	_	_	_
29	mitochondrial	_	_	JJ	_	_	_	_	_
30	superoxide	_	_	NN	_	_	_	_	_
31	production	_	_	NN	_	_	_	_	_
32	in	_	_	IN	_	_	_	_	_
33	diabetic	_	_	JJ	_	_	_	_	_
34	patients	_	_	NNS	_	_	_	_	_
35	after	_	_	IN	_	_	_	_	_
36	treatment	_	_	NN	_	_	_	_	_
37	with	_	_	IN	_	_	_	_	_
38	the	_	_	DT	_	_	_	_	_
39	iSGLT2	_	_	NNP	_	_	_	_	_
40	empagliflozin	_	_	NN	_	_	_	_	_
41	,	_	_	,	_	_	_	_	_
42	together	_	_	RB	_	_	_	_	_
43	with	_	_	IN	_	_	_	_	_
44	increased	_	_	VBN	_	_	_	_	_
45	antioxidant	_	_	JJ	_	_	_	_	_
46	defenses	_	_	NNS	_	_	_	_	_
47	.	_	_	.	_	_	_	_	_


1	Moreover	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	reduced	_	_	VBN	_	_	_	_	_
4	proinflammatory	_	_	JJ	_	_	_	_	_
5	markers	_	_	NNS	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	increased	_	_	VBN	_	_	_	_	_
8	anti-inflammatory	_	_	JJ	_	_	_	_	_
9	parameters	_	_	NNS	_	_	_	_	_
10	were	_	_	VBD	_	_	_	_	_
11	maintained	_	_	VBN	_	_	_	_	_
12	after	_	_	IN	_	_	_	_	_
13	24	_	_	CD	_	_	_	_	_
14	weeks	_	_	NNS	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	treatment	_	_	NN	_	_	_	_	_
17	with	_	_	IN	_	_	_	_	_
18	empagliflozin	_	_	NN	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	Besides	_	_	IN	_	_	_	_	_
2	their	_	_	PRP$	_	_	_	_	_
3	glucose-lowering	_	_	JJ	_	_	_	_	_
4	effect	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	iSGLT2s	_	_	NNPS	_	_	_	_	_
7	produce	_	_	VBP	_	_	_	_	_
8	changes	_	_	NNS	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	lipid	_	_	JJ	_	_	_	_	_
12	profile	_	_	NN	_	_	_	_	_
13	that	_	_	WDT	_	_	_	_	_
14	should	_	_	MD	_	_	_	_	_
15	also	_	_	RB	_	_	_	_	_
16	be	_	_	VB	_	_	_	_	_
17	highlighted	_	_	VBN	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	Empagliflozin	_	_	NNP	_	_	_	_	_
2	treatment	_	_	NN	_	_	_	_	_
3	is	_	_	VBZ	_	_	_	_	_
4	correlated	_	_	VBN	_	_	_	_	_
5	with	_	_	IN	_	_	_	_	_
6	increased	_	_	VBN	_	_	_	_	_
7	total	_	_	JJ	_	_	_	_	_
8	cholesterol	_	_	NN	_	_	_	_	_
9	due	_	_	JJ	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	slight	_	_	JJ	_	_	_	_	_
12	increases	_	_	NNS	_	_	_	_	_
13	in	_	_	IN	_	_	_	_	_
14	HDL-c	_	_	NNP	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	LDL-c	_	_	NNP	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	as	_	_	IN	_	_	_	_	_
19	we	_	_	PRP	_	_	_	_	_
20	have	_	_	VBP	_	_	_	_	_
21	observed	_	_	VBN	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	reported	_	_	VBN	_	_	_	_	_
25	in	_	_	IN	_	_	_	_	_
26	other	_	_	JJ	_	_	_	_	_
27	studies	_	_	NNS	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	there	_	_	EX	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	a	_	_	DT	_	_	_	_	_
6	well-documented	_	_	JJ	_	_	_	_	_
7	cardiovascular	_	_	JJ	_	_	_	_	_
8	protection	_	_	NN	_	_	_	_	_
9	exerted	_	_	VBN	_	_	_	_	_
10	by	_	_	IN	_	_	_	_	_
11	iSGLT2s	_	_	NNPS	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	which	_	_	WDT	_	_	_	_	_
14	endows	_	_	VBZ	_	_	_	_	_
15	these	_	_	DT	_	_	_	_	_
16	drugs	_	_	NNS	_	_	_	_	_
17	with	_	_	IN	_	_	_	_	_
18	clinical	_	_	JJ	_	_	_	_	_
19	potential	_	_	NN	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	has	_	_	VBZ	_	_	_	_	_
3	been	_	_	VBN	_	_	_	_	_
4	reflected	_	_	VBN	_	_	_	_	_
5	by	_	_	IN	_	_	_	_	_
6	several	_	_	JJ	_	_	_	_	_
7	studies	_	_	NNS	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	such	_	_	JJ	_	_	_	_	_
10	as	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	EMPA-REG	_	_	NNP	_	_	_	_	_
13	OUTCOME	_	_	NNP	_	_	_	_	_
14	study	_	_	NN	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	which	_	_	WDT	_	_	_	_	_
17	a	_	_	DT	_	_	_	_	_
18	reduction	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	38	_	_	CD	_	_	_	_	_
21	%	_	_	NN	_	_	_	_	_
22	in	_	_	IN	_	_	_	_	_
23	cardiovascular	_	_	JJ	_	_	_	_	_
24	mortality	_	_	NN	_	_	_	_	_
25	was	_	_	VBD	_	_	_	_	_
26	evident	_	_	JJ	_	_	_	_	_
27	in	_	_	IN	_	_	_	_	_
28	the	_	_	DT	_	_	_	_	_
29	empagliflozin	_	_	NN	_	_	_	_	_
30	vs.	_	_	IN	_	_	_	_	_
31	placebo	_	_	NN	_	_	_	_	_
32	group	_	_	NN	_	_	_	_	_
33	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	neither	_	_	CC	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	reduction	_	_	NN	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	HbA1c	_	_	NNP	_	_	_	_	_
8	observed	_	_	VBD	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	study	_	_	NN	_	_	_	_	_
12	(	_	_	-LRB-	_	_	_	_	_
13	0.60	_	_	CD	_	_	_	_	_
14	%	_	_	NN	_	_	_	_	_
15	over	_	_	IN	_	_	_	_	_
16	12	_	_	CD	_	_	_	_	_
17	weeks	_	_	NNS	_	_	_	_	_
18	)	_	_	-RRB-	_	_	_	_	_
19	nor	_	_	CC	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	reduction	_	_	NN	_	_	_	_	_
22	in	_	_	IN	_	_	_	_	_
23	SBP	_	_	NN	_	_	_	_	_
24	(	_	_	-LRB-	_	_	_	_	_
25	up	_	_	IN	_	_	_	_	_
26	to	_	_	TO	_	_	_	_	_
27	5	_	_	CD	_	_	_	_	_
28	mmHg	_	_	NN	_	_	_	_	_
29	)	_	_	-RRB-	_	_	_	_	_
30	are	_	_	VBP	_	_	_	_	_
31	sufficient	_	_	JJ	_	_	_	_	_
32	to	_	_	TO	_	_	_	_	_
33	explain	_	_	VB	_	_	_	_	_
34	the	_	_	DT	_	_	_	_	_
35	reported	_	_	VBN	_	_	_	_	_
36	protection	_	_	NN	_	_	_	_	_
37	against	_	_	IN	_	_	_	_	_
38	cardiovascular	_	_	JJ	_	_	_	_	_
39	mortality	_	_	NN	_	_	_	_	_
40	.	_	_	.	_	_	_	_	_


1	Interestingly	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	as	_	_	RB	_	_	_	_	_
4	little	_	_	RB	_	_	_	_	_
5	as	_	_	IN	_	_	_	_	_
6	24	_	_	CD	_	_	_	_	_
7	weeks	_	_	NNS	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	treatment	_	_	NN	_	_	_	_	_
10	with	_	_	IN	_	_	_	_	_
11	iSGLT2	_	_	NN	_	_	_	_	_
12	is	_	_	VBZ	_	_	_	_	_
13	sufficient	_	_	JJ	_	_	_	_	_
14	to	_	_	TO	_	_	_	_	_
15	witness	_	_	VB	_	_	_	_	_
16	their	_	_	PRP$	_	_	_	_	_
17	beneficial	_	_	JJ	_	_	_	_	_
18	effects	_	_	NNS	_	_	_	_	_
19	on	_	_	IN	_	_	_	_	_
20	HbA1c	_	_	NN	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	body	_	_	NN	_	_	_	_	_
23	weight	_	_	NN	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	blood	_	_	NN	_	_	_	_	_
26	pressure	_	_	NN	_	_	_	_	_
27	and	_	_	CC	_	_	_	_	_
28	,	_	_	,	_	_	_	_	_
29	most	_	_	RBS	_	_	_	_	_
30	importantly	_	_	RB	_	_	_	_	_
31	,	_	_	,	_	_	_	_	_
32	on	_	_	IN	_	_	_	_	_
33	the	_	_	DT	_	_	_	_	_
34	cardiovascular	_	_	JJ	_	_	_	_	_
35	system	_	_	NN	_	_	_	_	_
36	.	_	_	.	_	_	_	_	_


1	As	_	_	IN	_	_	_	_	_
2	an	_	_	DT	_	_	_	_	_
3	example	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	reduction	_	_	NN	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	hospitalization	_	_	NN	_	_	_	_	_
9	rates	_	_	NNS	_	_	_	_	_
10	for	_	_	IN	_	_	_	_	_
11	heart	_	_	NN	_	_	_	_	_
12	failure	_	_	NN	_	_	_	_	_
13	in	_	_	IN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	group	_	_	NN	_	_	_	_	_
16	treated	_	_	VBN	_	_	_	_	_
17	with	_	_	IN	_	_	_	_	_
18	empagliflozin	_	_	NN	_	_	_	_	_
19	in	_	_	IN	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	EMPA-REG	_	_	NNP	_	_	_	_	_
22	OUTCOME	_	_	NNP	_	_	_	_	_
23	study	_	_	NN	_	_	_	_	_
24	was	_	_	VBD	_	_	_	_	_
25	already	_	_	RB	_	_	_	_	_
26	significant	_	_	JJ	_	_	_	_	_
27	at	_	_	IN	_	_	_	_	_
28	this	_	_	DT	_	_	_	_	_
29	time	_	_	NN	_	_	_	_	_
30	point	_	_	NN	_	_	_	_	_
31	.	_	_	.	_	_	_	_	_


1	A	_	_	DT	_	_	_	_	_
2	recent	_	_	JJ	_	_	_	_	_
3	study	_	_	NN	_	_	_	_	_
4	demonstrated	_	_	VBD	_	_	_	_	_
5	an	_	_	DT	_	_	_	_	_
6	improved	_	_	VBN	_	_	_	_	_
7	arterial	_	_	JJ	_	_	_	_	_
8	stiffness	_	_	NN	_	_	_	_	_
9	after	_	_	IN	_	_	_	_	_
10	6	_	_	CD	_	_	_	_	_
11	weeks	_	_	NNS	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	treatment	_	_	NN	_	_	_	_	_
14	with	_	_	IN	_	_	_	_	_
15	empagliflozin	_	_	NN	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	T2D	_	_	NN	_	_	_	_	_
18	patients	_	_	NNS	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	hs-CRP	_	_	NN	_	_	_	_	_
22	was	_	_	VBD	_	_	_	_	_
23	shown	_	_	VBN	_	_	_	_	_
24	to	_	_	TO	_	_	_	_	_
25	be	_	_	VB	_	_	_	_	_
26	one	_	_	CD	_	_	_	_	_
27	of	_	_	IN	_	_	_	_	_
28	the	_	_	DT	_	_	_	_	_
29	main	_	_	JJ	_	_	_	_	_
30	significant	_	_	JJ	_	_	_	_	_
31	determinants	_	_	NNS	_	_	_	_	_
32	for	_	_	IN	_	_	_	_	_
33	this	_	_	DT	_	_	_	_	_
34	improvement	_	_	NN	_	_	_	_	_
35	.	_	_	.	_	_	_	_	_


1	Nevertheless	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	despite	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	available	_	_	JJ	_	_	_	_	_
6	evidence	_	_	NN	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	molecular	_	_	JJ	_	_	_	_	_
10	mechanisms	_	_	NNS	_	_	_	_	_
11	underlying	_	_	VBG	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	cardiovascular	_	_	JJ	_	_	_	_	_
14	protection	_	_	NN	_	_	_	_	_
15	attributable	_	_	JJ	_	_	_	_	_
16	to	_	_	TO	_	_	_	_	_
17	iSGLT2	_	_	NN	_	_	_	_	_
18	treatment	_	_	NN	_	_	_	_	_
19	are	_	_	VBP	_	_	_	_	_
20	still	_	_	RB	_	_	_	_	_
21	unknown	_	_	JJ	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	though	_	_	IN	_	_	_	_	_
24	amelioration	_	_	NN	_	_	_	_	_
25	of	_	_	IN	_	_	_	_	_
26	oxidative	_	_	JJ	_	_	_	_	_
27	stress	_	_	NN	_	_	_	_	_
28	has	_	_	VBZ	_	_	_	_	_
29	been	_	_	VBN	_	_	_	_	_
30	hypothesized	_	_	VBN	_	_	_	_	_
31	to	_	_	TO	_	_	_	_	_
32	be	_	_	VB	_	_	_	_	_
33	a	_	_	DT	_	_	_	_	_
34	potential	_	_	JJ	_	_	_	_	_
35	contributor	_	_	NN	_	_	_	_	_
36	.	_	_	.	_	_	_	_	_


1	Because	_	_	IN	_	_	_	_	_
2	cardiac	_	_	JJ	_	_	_	_	_
3	tissue	_	_	NN	_	_	_	_	_
4	possesses	_	_	VBZ	_	_	_	_	_
5	low	_	_	JJ	_	_	_	_	_
6	antioxidant	_	_	NN	_	_	_	_	_
7	defenses	_	_	NNS	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	increasing	_	_	VBG	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	expression	_	_	NN	_	_	_	_	_
12	or	_	_	CC	_	_	_	_	_
13	activity	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	antioxidant	_	_	JJ	_	_	_	_	_
16	enzymes	_	_	NNS	_	_	_	_	_
17	could	_	_	MD	_	_	_	_	_
18	be	_	_	VB	_	_	_	_	_
19	a	_	_	DT	_	_	_	_	_
20	mechanism	_	_	NN	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	cardiac	_	_	JJ	_	_	_	_	_
23	protection	_	_	NN	_	_	_	_	_
24	under	_	_	IN	_	_	_	_	_
25	high	_	_	JJ	_	_	_	_	_
26	risk	_	_	NN	_	_	_	_	_
27	situations	_	_	NNS	_	_	_	_	_
28	such	_	_	JJ	_	_	_	_	_
29	as	_	_	IN	_	_	_	_	_
30	T2D	_	_	NN	_	_	_	_	_
31	.	_	_	.	_	_	_	_	_


1	Oxidative	_	_	JJ	_	_	_	_	_
2	stress	_	_	NN	_	_	_	_	_
3	occurs	_	_	VBZ	_	_	_	_	_
4	when	_	_	WRB	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	production	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	pro-oxidant	_	_	JJ	_	_	_	_	_
9	species	_	_	NNS	_	_	_	_	_
10	overcomes	_	_	VBZ	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	intrinsic	_	_	JJ	_	_	_	_	_
13	antioxidant	_	_	JJ	_	_	_	_	_
14	defense	_	_	NN	_	_	_	_	_
15	system	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	cell	_	_	NN	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	thus	_	_	RB	_	_	_	_	_
21	triggering	_	_	VBG	_	_	_	_	_
22	damage	_	_	NN	_	_	_	_	_
23	to	_	_	TO	_	_	_	_	_
24	lipids	_	_	NNS	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	proteins	_	_	NNS	_	_	_	_	_
27	and	_	_	CC	_	_	_	_	_
28	DNA	_	_	NN	_	_	_	_	_
29	,	_	_	,	_	_	_	_	_
30	and	_	_	CC	_	_	_	_	_
31	eventually	_	_	RB	_	_	_	_	_
32	compromising	_	_	VBG	_	_	_	_	_
33	cellular	_	_	JJ	_	_	_	_	_
34	and	_	_	CC	_	_	_	_	_
35	tissue	_	_	NN	_	_	_	_	_
36	function	_	_	NN	_	_	_	_	_
37	.	_	_	.	_	_	_	_	_


1	Exploring	_	_	VBG	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	role	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	SGLT2	_	_	NN	_	_	_	_	_
6	inhibition	_	_	NN	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	prevention	_	_	NN	_	_	_	_	_
10	or	_	_	CC	_	_	_	_	_
11	reduction	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	oxidative	_	_	JJ	_	_	_	_	_
14	stress	_	_	NN	_	_	_	_	_
15	conditions	_	_	NNS	_	_	_	_	_
16	has	_	_	VBZ	_	_	_	_	_
17	been	_	_	VBN	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	subject	_	_	NN	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	several	_	_	JJ	_	_	_	_	_
22	studies	_	_	NNS	_	_	_	_	_
23	over	_	_	IN	_	_	_	_	_
24	the	_	_	DT	_	_	_	_	_
25	last	_	_	JJ	_	_	_	_	_
26	decade	_	_	NN	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	to	_	_	TO	_	_	_	_	_
4	date	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	most	_	_	JJS	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	studies	_	_	NNS	_	_	_	_	_
10	evaluating	_	_	VBG	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	effect	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	iSGLT2	_	_	NN	_	_	_	_	_
15	on	_	_	IN	_	_	_	_	_
16	oxidative	_	_	JJ	_	_	_	_	_
17	stress	_	_	NN	_	_	_	_	_
18	have	_	_	VBP	_	_	_	_	_
19	been	_	_	VBN	_	_	_	_	_
20	performed	_	_	VBN	_	_	_	_	_
21	in	_	_	IN	_	_	_	_	_
22	animal	_	_	NN	_	_	_	_	_
23	models	_	_	NNS	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	Our	_	_	PRP$	_	_	_	_	_
2	data	_	_	NNS	_	_	_	_	_
3	demonstrate	_	_	VBP	_	_	_	_	_
4	that	_	_	IN	_	_	_	_	_
5	T2D	_	_	NN	_	_	_	_	_
6	patients	_	_	NNS	_	_	_	_	_
7	receiving	_	_	VBG	_	_	_	_	_
8	iSGLT2	_	_	NN	_	_	_	_	_
9	treatment	_	_	NN	_	_	_	_	_
10	undergo	_	_	VBP	_	_	_	_	_
11	a	_	_	DT	_	_	_	_	_
12	reduction	_	_	NN	_	_	_	_	_
13	in	_	_	IN	_	_	_	_	_
14	mitochondrial	_	_	JJ	_	_	_	_	_
15	superoxide	_	_	NN	_	_	_	_	_
16	production	_	_	NN	_	_	_	_	_
17	in	_	_	IN	_	_	_	_	_
18	parallel	_	_	JJ	_	_	_	_	_
19	to	_	_	TO	_	_	_	_	_
20	an	_	_	DT	_	_	_	_	_
21	increase	_	_	NN	_	_	_	_	_
22	in	_	_	IN	_	_	_	_	_
23	glutathione	_	_	NN	_	_	_	_	_
24	content	_	_	NN	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	and	_	_	CC	_	_	_	_	_
27	markedly	_	_	RB	_	_	_	_	_
28	so	_	_	RB	_	_	_	_	_
29	after	_	_	IN	_	_	_	_	_
30	24	_	_	CD	_	_	_	_	_
31	weeks	_	_	NNS	_	_	_	_	_
32	of	_	_	IN	_	_	_	_	_
33	treatment	_	_	NN	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	accompanied	_	_	VBN	_	_	_	_	_
4	by	_	_	IN	_	_	_	_	_
5	increased	_	_	VBN	_	_	_	_	_
6	expression	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	antioxidant	_	_	NN	_	_	_	_	_
10	enzymes	_	_	NNS	_	_	_	_	_
11	GSR	_	_	NNP	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	CAT	_	_	NN	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	no	_	_	DT	_	_	_	_	_
4	changes	_	_	NNS	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	plasma	_	_	NN	_	_	_	_	_
7	protein	_	_	NN	_	_	_	_	_
8	carbonyl	_	_	NN	_	_	_	_	_
9	content	_	_	NN	_	_	_	_	_
10	were	_	_	VBD	_	_	_	_	_
11	observed	_	_	VBN	_	_	_	_	_
12	with	_	_	IN	_	_	_	_	_
13	empagliflozin	_	_	NN	_	_	_	_	_
14	treatment	_	_	NN	_	_	_	_	_
15	at	_	_	IN	_	_	_	_	_
16	these	_	_	DT	_	_	_	_	_
17	time-points	_	_	NNS	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	Whether	_	_	IN	_	_	_	_	_
2	this	_	_	DT	_	_	_	_	_
3	could	_	_	MD	_	_	_	_	_
4	be	_	_	VB	_	_	_	_	_
5	due	_	_	JJ	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	small	_	_	JJ	_	_	_	_	_
9	sample	_	_	NN	_	_	_	_	_
10	size	_	_	NN	_	_	_	_	_
11	or	_	_	CC	_	_	_	_	_
12	would	_	_	MD	_	_	_	_	_
13	require	_	_	VB	_	_	_	_	_
14	long-term	_	_	JJ	_	_	_	_	_
15	empagliflozin	_	_	NN	_	_	_	_	_
16	treatment	_	_	NN	_	_	_	_	_
17	needs	_	_	VBZ	_	_	_	_	_
18	to	_	_	TO	_	_	_	_	_
19	be	_	_	VB	_	_	_	_	_
20	addressed	_	_	VBN	_	_	_	_	_
21	in	_	_	IN	_	_	_	_	_
22	future	_	_	JJ	_	_	_	_	_
23	research	_	_	NN	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	Our	_	_	PRP$	_	_	_	_	_
2	findings	_	_	NNS	_	_	_	_	_
3	are	_	_	VBP	_	_	_	_	_
4	in	_	_	IN	_	_	_	_	_
5	accordance	_	_	NN	_	_	_	_	_
6	with	_	_	IN	_	_	_	_	_
7	previous	_	_	JJ	_	_	_	_	_
8	studies	_	_	NNS	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	rat	_	_	NN	_	_	_	_	_
11	models	_	_	NNS	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	T2D	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	which	_	_	WDT	_	_	_	_	_
17	increased	_	_	VBD	_	_	_	_	_
18	antioxidant	_	_	NN	_	_	_	_	_
19	enzyme	_	_	NN	_	_	_	_	_
20	content	_	_	NN	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	activity	_	_	NN	_	_	_	_	_
23	in	_	_	IN	_	_	_	_	_
24	renal	_	_	JJ	_	_	_	_	_
25	tissues	_	_	NNS	_	_	_	_	_
26	has	_	_	VBZ	_	_	_	_	_
27	been	_	_	VBN	_	_	_	_	_
28	reported	_	_	VBN	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	Furthermore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	iSGLT2	_	_	NN	_	_	_	_	_
4	treatment	_	_	NN	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	diabetic	_	_	JJ	_	_	_	_	_
7	mice	_	_	NNS	_	_	_	_	_
8	has	_	_	VBZ	_	_	_	_	_
9	been	_	_	VBN	_	_	_	_	_
10	shown	_	_	VBN	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	induce	_	_	VB	_	_	_	_	_
13	antioxidant	_	_	JJ	_	_	_	_	_
14	gene	_	_	NN	_	_	_	_	_
15	expression	_	_	NN	_	_	_	_	_
16	(	_	_	-LRB-	_	_	_	_	_
17	manganese-dependent	_	_	JJ	_	_	_	_	_
18	superoxide	_	_	NN	_	_	_	_	_
19	dismutase	_	_	NN	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	CAT	_	_	NN	_	_	_	_	_
22	)	_	_	-RRB-	_	_	_	_	_
23	in	_	_	IN	_	_	_	_	_
24	adipose	_	_	NN	_	_	_	_	_
25	tissue	_	_	NN	_	_	_	_	_
26	and	_	_	CC	_	_	_	_	_
27	muscle	_	_	NN	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_

